World
CONTACTStaffCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2024 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
FDA approves Fuzeon
The Food and Drug Administration on Thursday approved Roche and Trimeris's HIV entry inhibitor Fuzeon, making the drug the first entry inhibitor ever to hit the U.S. market. Trimeris and Roche officials say they plan to begin shipping Fuzeon in late March or early April. The FDA based its approval on an analysis of six months of data from two ongoing clinical trials of Fuzeon involving about 1,000 patients who were experiencing resistance to other anti-HIV medications. The data from this analysis showed that the addition of Fuzeon to a combination of other antiretroviral medications reduced blood-based HIV viral loads.
AIDS activists, however, are anxiously awaiting final word from the drug companies on the cost of the medication. The recent announcement that the drug will cost more than $20,000 per patient per year in Europe has U.S. health care providers and HIV-positive people concerned that the U.S. price will make the drug unaffordable for many low-income, uninsured, or underinsured patients. The expected high cost of the drug also may keep Medicaid programs and state-managed AIDS Drug Assistance Programs from covering it. "We don't think we can add Fuzeon [to our drug list] without cutting something else," Michael Montgomery, head of California's ADAP, told The [Raleigh, N.C.] News & Observer. "We are excited about the drug, but we aren't sure we can afford it." The drug developers say the high cost of the medication is due to its difficult manufacturing process.
Fuzeon, previously known as T-20, is the world's first HIV entry inhibitor. The drug works by preventing HIV from being able to attach to receptors on the surface of T cells, thereby preventing infection. All other existing HIV drugs work by interfering with HIV replication in cells already infected with the virus. The injectable medication was designed as a treatment for patients who have failed other anti-HIV regimens. A Fuzeon follow-up product, called T-1249, is currently in development and has been shown in clinical trials to reduce viral levels in patients who have developed resistance to other anti-HIV medications, including Fuzeon.
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Meet all 37 of the queer women in this season's WNBA
April 17 2024 11:24 AM
Here are the 15 gayest travel destinations in the world: report
March 26 2024 9:23 AM
21+ steamy photos of Scotland’s finest gay men in Elska Glasgow
February 01 2024 10:07 PM
More Than 50 of Our Favorite LGBTQ+ Moms
May 12 2024 11:44 AM
Conjoined twins Lori Schappell and trans man George Schappell dead at 62
April 27 2024 6:13 PM
Latest Stories
Kamala Harris rides wave of Democratic energy at kickoff event in Wisconsin
July 23 2024 3:36 PM
'Devastated:' A six-week abortion ban will go into effect in Iowa next week
July 23 2024 2:28 PM
Four hours, 44,000 Black women, and one Zoom call
July 23 2024 2:17 PM
Record 1.2 million people show out for Cologne’s Pride parade
July 23 2024 10:51 AM
Here's how far-right activist Leonard Leo helped fund Bud Light boycott
July 23 2024 10:27 AM
Elon Musk’s comments about his trans daughter prove why she doesn’t speak to him
July 23 2024 9:16 AM
Nancy Pelosi endorses Kamala Harris for president
July 22 2024 4:07 PM
Charli XCX declares Kamala Harris IS brat & our next President's campaign agrees
July 22 2024 3:08 PM